Galapagos jumps on collaboration with Blood Centers of America
** Shares in Galapagos GLPG.AS rise about 3%, after the Belgium-based drugmaker announced a collaboration with Blood Centers of America (BCA)
** This collaboration gives Galapagos access to BCA's network of over 50 sites in the U.S. for the decentralised manufacturing (POC) of its chimeric antigen receptor T (CAR-T) cell therapies, the company says
** "We believe this collaboration could unlock significant manufacturing capacity for Galapagos in the U.S.," says KBC Securities
** "Our back of the envelope calculation points to a capacity of 8K CAR-Ts per year with just 4 Cocoon's in each site," adds KBC
** The brokerage ups Galapagos to "buy" from "accumulate", pointing to "a big step towards demonstrating the scalability of Galapagos' decentralised manufacturing model"
** Stock is top performer on BEL 20 index .BFX
Reporting by Clement Martinot
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
